FDA Adds Boxed Warning to Canagliflozin for Increased Amputation Risk — Physician’s First Watch

Medical News |
May 17, 2017

FDA Adds Boxed Warning to Canagliflozin for Increased Amputation Risk

By Kristin J. Kelley

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

The FDA is adding new warnings — including a boxed warning — to labels for the type 2 diabetes drug canagliflozin (Invokana and Invokamet) to caution about the increased risk for leg and foot amputations. The action is a response to results from the clinical trials CANVAS and CANVAS-R.

After 1 year, patients treated with canagliflozin had nearly twice the amputation rate as those given placebo (5.9 vs. 2.8 cases per 1,000 patients in the CANVAS trial). The toe and the middle of the foot were the most commonly amputated.

Patients using the drug should be aware of and report infections, pain, tenderness, sores, or ulcers affecting the feet or legs. Clinicians should consider a patient's risk factors before prescribing canagliflozin, including diabetic foot ulcers, neuropathy, peripheral vascular disease, or a prior amputation.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.